Objective: New biopharmaceuticals hold promise for preventing or treating necrotizing enterocolitis. However, it is unclear whether any such biopharmaceutical that requires enteral administration could be administered using an 'early-treatment' paradigm. This study was undertaken to assess this issue based on data from every case of Bell stage III NEC cared for during the past 7 years at Intermountain Healthcare.
Introduction
Preventing or effectively treating necrotizing enterocolitis (NEC) is a national health priority, 1 but despite decades of work, the means of doing so remain uncertain. [2] [3] [4] Various biopharmaceutical means have been successful in animal models of NEC. [5] [6] [7] [8] However, designing clinical trials has proven challenging. For example, agents that are to be administered prophylactically present a 'high NNT (number needed to treat)' problem. The experimental agent would have to be administered for many days to perhaps 20 to 50 VLBW neonates to potentially prevent one case of NEC. A more appealing study design might be an 'early treatment' paradigm, where administration would begin only after the first signs of NEC appear. An early treatment approach can be more acceptable than a prophylactic approach when trialing new drugs among vulnerable populations. 9 This is because early treatment would target patients with a high likelihood of actually developing NEC, thereby reducing the odds of using an experimental agent among neonates who have nothing to gain by that agent.
This study was designed to discover an evidence base that would predict the feasibility of an early treatment trial using an enterally administered experimental agent. To accomplish this, we located the records of all cases of Bell stage III NEC cared for in the Intermountain Healthcare system over the past 7 years. For each case, we identified the date NEC was first documented. Then, using nursing notes, nursing flow sheets, laboratory studies, radiographs and physician notes, we determined the first presenting clinical and laboratory signs for each case, and calculated the time between those antecedent signs and the placement of a multiple side-hole catheter for intermittent gastric decompression (Anderson tube, Replogle tube or Vigon tube; referred to hereafter as an Anderson tube). We reasoned that once the Anderson tube is placed, enteral administration would be unworkable, because any medication placed into the stomach would largely or entirely be removed by the intermittent gastric suctioning.
Methods
A list of patients with NEC and surgery and a date of birth from 1 January 2001 through 31 December 2007 was obtained from the electronic medical record repositories of Intermountain Healthcare. All patients with NEC and surgery had paper charts retrieved. If the operative report indicated focal gastrointestinal perforation, based on the surgeon's visual inspection of the bowel at the time of surgery, the condition was not listed as NEC but as focal gastrointestinal perforation and the patient was not considered further as part of this study. 10, 11 All NEC surgery in the state of Utah is performed at Intermountain Healthcare's Primary Children's Medical Center. If a patient developed NEC at a hospital outside the Intermountain Healthcare hospital network or the University of Utah Hospital and was subsequently transferred to the Primary Children's Medical Center, that patient was included in the study only if full outside records were present. From the paper records, the date and time NEC was diagnosed and recorded, referencing the time the Anderson tube was placed. Then, using nursing notes, flow sheets, laboratory data, radiographs and physician notes, two additional determinations were made for each patient: (1) Any signs of new pathology within 48 h preceding the diagnosis of NEC were recorded and (2) The time interval between each of those and the placement of the Anderson tube was recorded. The Intermountain Healthcare Institutional Review Board and the University of Utah Institutional Review Board approved the study.
The program for data collection was a modified subsystem of a Clinical Workstation. The 3M Company (Minneapolis, MN, USA) approved the structure and definitions of all data points for use within the program. Data were managed and accessed by authorized data analysts. Means and s.d. were used to express values in groups that were normally distributed, whereas medians and ranges were used to express values in groups that were not. Differences in categorical variables were assessed using Fisher's exact test. Student's t-test was used to assess continuous variables. Statistical significance was set as P<0.05.
Results
Electronic records identified 133 patients diagnosed with NEC who had surgery and a date of birth within the specified limits. Fifteen cases were excluded from further review. The explanations were as follows: (1) One case had NEC and surgery, but the surgery was not related to NEC. (2) Eight cases had surgical and pathological reports indicating a diagnosis other than NEC (two strangulated hernia, two jejuna atresia, two gastroschisis, two isolated ileal perforation). (3) Six cases of NEC occurred at a hospital outside the University of Utah and Intermountain Healthcare hospital systems and we did not have access to all of the nursing records, laboratory findings and radiographs at the time NEC was diagnosed. The sum of these eliminations left a group of 118 patients with proven Bell stage III NEC where full records were available for review. These 118 constituted the basis of the subsequent studies.
An Anderson tube was placed, and intermittent gastric suctioning was applied before surgery, in all patients. The date and time of this tube placement were identified in all patients, and antecedents during the 48 h period preceding that tube placement were identified in each. The antecedents recorded most frequently were: an increase in apnea/bradycardia spells (identified in 42% of cases, 2.8±2.1 h before placement of the gastric sump tube), new onset irritability (identified in 46% of cases, 5.4 ± 3.7 h before gastric tube placement) and new onset mottling of the skin (identified in 42% of cases, 4.5 ± 3.1 hours before tube placement). Tachycardia, tachypnea and hypotension were recorded uncommonly as antecedents.
Forty-five of the patients (38%) received a blood transfusion within 48 hours preceding the Anderson tube placement. Forty-one (35%) received an erythrocyte transfusion and four (3%) received a platelet transfusion, whereas none received plasma or cryoprecipitate in this 48 h period. None of these erythrocyte or platelet transfusions were for treatment of hemorrhagic complications; rather, all were prophylactic, meaning that the hemoglobin, hematocrit or platelet count fell below the transfusion 'trigger' level. 12 The transfusions were finished 18 ± 12 h before the Anderson tube was placed. One patient had two episodes of supraventricular tachycardia as antecedents of the NEC, each being successfully treated with adenosine but not with ice to the face. These episodes occurred 20 h and again 8 h before the Anderson tube was placed.
Three gastrointestinal abnormalities were found consistently within 48 h preceding placement of the Anderson tube. In 66% of cases, increased abdominal girth was recorded (2.8 ± 3.1 h before tube placement); 48% had a new onset of emesis or elevated prefeeding gastric residuals (4.9 ± 4.0 h), and 32% had observed blood in the stool (2.0 ± 1.9 h). Diarrhea was not discovered as a consistent antecedent of NEC.
We found no laboratory antecedents of NEC. None of the patients were receiving frequent, routine laboratory tests immediately before NEC was diagnosed. A CBC and a CRP (and often other laboratory tests) were always obtained after NEC was suspected, at about the time the Anderson tube was placed. Thus, in no case did we identify an abnormal blood neutrophil count, a leukocyte left shift, a low platelet count or an elevated mean platelet volume as antecedents of NEC.
Discussion
On the basis of the findings of this study, we judge that an early treatment approach to NEC, using an enterally administered biopharmaceutical, would probably not be feasible. The two main reasons for this are: (1) the common antecedents of Bell stage III NEC are nonspecific for gastrointestinal pathology, and (2) when signs of gastrointestinal pathology appear, insufficient time exists for enteral dosing before an Anderson tube is placed. Once gastric suction is installed, it is unlikely that adequate enteral dosing could be accomplished, particularly when an ileus might further diminish drug delivery. Our results do not exclude the potential use of experimental NEC treatments administered parenterally, such as pentoxifylline or 2-bromopalmitate. These would be reasonable to pursue during this window because they do not rely on gastrointestinal absorption.
We recognize significant limitations and pitfalls of this study. First, it is a historic cohort study, and thus we were limited to the information in the records. For instance, some nurses were surely more observant or more fastidious than others about writing such findings as 'irritability' or an increase in apnea/bradycardia spells. Similarly, measurements of abdominal circumference were sometimes charted, but in other cases the notes simply said 'increased abdominal girth.' The same is the case for pre-feeding gastric residual volumes, which were charted infrequently. Also, the heart rate, respiratory rate and blood pressure measurements were recorded periodically, generally every 3 hours. Although we did not find gross changes in these preceding the diagnosis of NEC, perhaps subtle changes, unrecorded by intermittent charting, indeed occurred. Another pitfall present in our conclusion is that no laboratory determinations preceded the diagnosis of NEC. In fact, laboratory determinations were almost never made immediately before but only after NEC was suspected. Thus, we have no way of knowing whether laboratory changes preceded the nonspecific antecedents or the gastrointestinal signs.
On the basis of the antecedents we found, it seems to us that studies where a biopharmaceutical is administered enterally must be based on a prophylaxis paradigm, not on an early treatment paradigm. We recognize that a significant drawback to a prophylaxis design is the 'large NNT problem.' The overall prevalence of NEC (Stage II and III) is about 7% of VLBW neonates. 1, 2, 11, 13, 14 If a targeted prophylactic medication was 50% effective in reducing NEC (making it highly effective), we would have to treat 30 VLBW neonates prophylactically with that agent to prevent one case of NEC. Although that approach might indeed ultimately prove to be wise and cost-effective, owing to the high costs of Bell stage III NEC, enrollment in the initial clinical trials could be problematic. For instance, concerns might arise in asking a parent for permission to repeatedly administer an experimental medication to their VLBW neonate with the expectation of preventing only one case of NEC for every 30 neonates so treated.
To ameliorate the 'high NNT problem,' we suggest that a modified prophylaxis strategy should be devised, whereby study eligibility would be limited to neonates at very high risk for developing NEC. This approach also has pitfalls, the foremost of which is accurately predicting the odds of developing NEC.
Potential factors that could be tested in multivariate models might include gestational age and birth weight, 1,2 lack of mother's own milk, [14] [15] [16] [17] maternal substance abuse, 17,18 teenaged mother, 4 and being born outside a level III perinatal center. 19 From this study, and also from the reports of Mally et al. 20 and Kenton et al., 21 blood transfusions might also place NICU patients at risk for developing Stage III NEC, particularly when transfusions are given to otherwise stable, growing, feeding and preterm infants. If a mathematical model based on these or other features and issues could estimate the NEC risk, perhaps neonates found to be at very high risk could be considered eligible. In view of this study's findings, and the reasoning presented here, we conclude that those should be prophylaxis trials.
